Informace o publikaci

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Autoři	BUSCA Alessandro SALMANTON-GARCIA Jon MARCHESI Francesco FARINA Francesca SEVAL Guldane Cengiz JAAP Van Doesum DE JONGE Nick C BAHR Nathan C MAERTENS Johan MELETIADIS Joseph S FRACCHIOLLA Nicola S WEINBERGEROVÁ Barbora VERGA Luisa RACIL Zdenek JIMENEZ Moraima GLENTHOJ Andreas BLENNOW Ola TANASE Alina Daniela SCHOENLEIN Martin PREZIOSO Lucia KHANNA Nina F DUARTE Rafael F ZAK Pavel NUCCI Marcio MACHADO Marina KULASEKARARAJ Austin ESPIGADO Ildefonso ELIZABETH De Kort SUSANA Jose-Maria Ribera-Santa MARCHETTI Monia MAGLIANO Gabriele FALCES-ROMERO Iker ILHAN Osman AMMATUNA Emanuele ZOMPI Sofia TSIRIGOTIS Panagiotis ANTONIADOU Anastasia ZAMBROTTA Giovanni Paolo Maria NORDLANDER Anna KARLSSON Linda Katharina HANAKOVA Michaela DRAGONETTI Giulia CABIRTA Alba CAROLINE Berg Venemyr GRAEFE Stefanie JENS Van Praet TRAGIANNIDIS Athanasios PETZER Verena LOPEZ-GARCIA Alberto ITRI Federico GROH Ana GAVRIILAKI Eleni DARGENIO Michelina RAHIMLI Laman A CORNELY Oliver A PAGANO Livio
Rok publikování	2023
Druh	Článek v odborném periodiku
Časopis / Zdroj	Frontiers in immunology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1125030/full
Doi	http://dx.doi.org/10.3389/fimmu.2023.1125030
Klíčová slova	allogeneic HSCT; COVID-19 infection; immunocompromised patients; SARS-CoV-2; hematological malignances
Popis	BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. MethodsThis multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). ConclusionsMortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.